emjreviews.com
Cure8 news brief
What Even Is ‘Moderate’ IBD? Experts Can’t Agree
Research and clinical trials
Clinical study
Clinicians
Researchers
Adult patients
Newly Diagnosed
Crohn's disease
Ulcerative colitis
Why This Matters
How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might benefit from earlier escalation.
Who Should Pay Attention
Clinicians who treat IBD, researchers designing trials or registries, adult patients and caregivers interested in disease classification and treatment thresholds, and those newly diagnosed who want to understand how severity is judged.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
The study reviewed >240 publications and identified multiple competing definitions (six for Crohn’s, 16 for UC) that sometimes overlap with thresholds used for severe disease. Authors and experts argue a unified, clinically relevant definition is needed to inform treatment decisions and to identify patients who may benefit from earlier biologic therapy.
The article does not report new trial data or specific treatment changes; it summarizes the review’s findings and expert commentary. Practical takeaway: This is about how researchers and clinicians categorize disease severity, not a new treatment or guideline.
It may influence future research, trial design, and how clinicians decide on escalation of therapy, but it does not itself change clinical recommendations.
Keep In Mind
This article summarizes a review published in Journal of Clinical Gastroenterology. Findings point to the need for broader, patient-centered severity criteria but do not provide a new consensus definition or immediate clinical guidance.
Study limitations, such as heterogeneity of included publications and lack of prospective testing of proposed frameworks, are implied; readers should consult the original paper for full methods and details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationemjreviews.com
Indexed viaBing News
Source typeResearch news
PublishedApr 22, 2026, 7:57 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
‘Getting closer’: Genetic risk scores may help predict inflammatory bowel disease severity
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
Mobius Care Receives Funding from Crohn's & Colitis Foundation
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...